FY2026 Earnings Estimate for Geron Issued By Leerink Partnrs

Geron Co. (NASDAQ:GERN) – Analysts at Leerink Partnrs lifted their FY2026 earnings estimates for shares of Geron in a report released on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of $0.36 for the year, up from their prior forecast of $0.33. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Other research analysts have also recently issued research reports about the company. Leerink Partners initiated coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Scotiabank initiated coverage on shares of Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a report on Tuesday. Finally, Barclays raised Geron to a “strong-buy” rating in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.15.

Geron Price Performance

Geron stock opened at $3.92 on Wednesday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.37 billion, a P/E ratio of -12.25 and a beta of 0.51. The firm has a fifty day moving average of $4.08 and a 200-day moving average of $4.34. Geron has a 52-week low of $1.64 and a 52-week high of $5.34.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company’s revenue was up 17138.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) EPS.

Institutional Investors Weigh In On Geron

Institutional investors and hedge funds have recently bought and sold shares of the business. Baader Bank Aktiengesellschaft bought a new stake in shares of Geron in the 2nd quarter worth approximately $86,000. Values First Advisors Inc. acquired a new stake in shares of Geron in the second quarter valued at approximately $115,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Geron during the second quarter worth approximately $1,076,000. Bank of New York Mellon Corp increased its position in Geron by 26.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,016,622 shares of the biopharmaceutical company’s stock valued at $8,550,000 after acquiring an additional 415,883 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Geron by 7.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,924 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 7,115 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.